PL3087182T3 - Sposoby i kompozycje do leczenia raka wykorzystujące środki oparte na kwasie peptydonukleinowym - Google Patents
Sposoby i kompozycje do leczenia raka wykorzystujące środki oparte na kwasie peptydonukleinowymInfo
- Publication number
- PL3087182T3 PL3087182T3 PL14875786T PL14875786T PL3087182T3 PL 3087182 T3 PL3087182 T3 PL 3087182T3 PL 14875786 T PL14875786 T PL 14875786T PL 14875786 T PL14875786 T PL 14875786T PL 3087182 T3 PL3087182 T3 PL 3087182T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- nucleic acid
- treating cancer
- peptide nucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920289P | 2013-12-23 | 2013-12-23 | |
| PCT/US2014/070970 WO2015100113A2 (en) | 2013-12-23 | 2014-12-17 | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
| EP14875786.7A EP3087182B1 (en) | 2013-12-23 | 2014-12-17 | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3087182T3 true PL3087182T3 (pl) | 2019-11-29 |
Family
ID=53479769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14875786T PL3087182T3 (pl) | 2013-12-23 | 2014-12-17 | Sposoby i kompozycje do leczenia raka wykorzystujące środki oparte na kwasie peptydonukleinowym |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10113169B2 (pl) |
| EP (2) | EP3087182B1 (pl) |
| JP (1) | JP6537513B2 (pl) |
| AU (2) | AU2014370182B2 (pl) |
| CA (2) | CA3142856A1 (pl) |
| DK (1) | DK3087182T3 (pl) |
| ES (1) | ES2741811T3 (pl) |
| PL (1) | PL3087182T3 (pl) |
| WO (1) | WO2015100113A2 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087182B1 (en) * | 2013-12-23 | 2019-03-20 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
| JP7537074B2 (ja) | 2016-05-10 | 2024-08-21 | ソルボンヌ ウニベルシテ | Cd47を活性化する作用物質およびその炎症治療における使用 |
| CA3145477A1 (en) * | 2019-07-24 | 2021-01-28 | Jeffrey Harold ROTHMAN | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
| CN115943152A (zh) * | 2020-05-18 | 2023-04-07 | 肿瘤基因公司 | 使用基于肽核酸的药剂治疗SARS-CoV-2感染的方法和组合物 |
| JP2022025558A (ja) * | 2020-07-29 | 2022-02-10 | 学校法人帝京大学 | miR-96-5pインヒビターとそれを含有する医薬組成物 |
| US20240148917A1 (en) * | 2020-10-16 | 2024-05-09 | Zytox Therapeutics Ab | Pna probes for pretargeted imaging and therapy |
| WO2023069452A1 (en) * | 2021-10-19 | 2023-04-27 | Oncogenuity, Inc. | Salt bridge modified peptide nucleic acid compositions and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU6668A1 (ru) | 1921-07-19 | 1924-09-15 | А.Д. Несмеянов | Центробежный распылитель дл жидкости |
| SU5416A1 (ru) | 1926-06-03 | 1928-05-31 | Тормейер Г. | Двигатель компаунд внутреннего горени |
| US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5308608A (en) | 1989-06-07 | 1994-05-03 | University Of British Columbia | Photosensitizing Diels-Alder porphyrin derivatives |
| US5726304A (en) | 1992-10-30 | 1998-03-10 | The University Of British Columbia | Porphocyanine and CNC-expanded porphyrins |
| US5405957A (en) | 1992-10-30 | 1995-04-11 | The University Of British Columbia | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5648485A (en) | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| AU741070B2 (en) | 1997-05-07 | 2001-11-22 | Qlt Inc. | Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents |
| US5880145A (en) | 1997-05-07 | 1999-03-09 | The University Of British Columbia | Class of benzoporphyrin derivative photoactive compounds |
| WO2008043366A2 (en) * | 2006-10-13 | 2008-04-17 | Københavns Universitet | Three-domain compounds for transmembrane delivery |
| JP5513129B2 (ja) * | 2007-02-08 | 2014-06-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 黒色腫におけるgnaq変異 |
| CN102449170A (zh) * | 2009-04-15 | 2012-05-09 | 西北大学 | 寡核苷酸功能化的纳米颗粒的递送 |
| EP3087182B1 (en) * | 2013-12-23 | 2019-03-20 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
-
2014
- 2014-12-17 EP EP14875786.7A patent/EP3087182B1/en not_active Not-in-force
- 2014-12-17 WO PCT/US2014/070970 patent/WO2015100113A2/en not_active Ceased
- 2014-12-17 AU AU2014370182A patent/AU2014370182B2/en not_active Ceased
- 2014-12-17 DK DK14875786.7T patent/DK3087182T3/da active
- 2014-12-17 US US15/104,701 patent/US10113169B2/en active Active
- 2014-12-17 ES ES14875786T patent/ES2741811T3/es active Active
- 2014-12-17 CA CA3142856A patent/CA3142856A1/en active Pending
- 2014-12-17 CA CA2934524A patent/CA2934524C/en active Active
- 2014-12-17 PL PL14875786T patent/PL3087182T3/pl unknown
- 2014-12-17 JP JP2016542243A patent/JP6537513B2/ja not_active Expired - Fee Related
- 2014-12-17 EP EP19163891.5A patent/EP3581653A3/en not_active Withdrawn
-
2018
- 2018-10-29 US US16/173,643 patent/US10858655B2/en active Active
-
2020
- 2020-08-07 US US16/988,395 patent/US11518996B2/en active Active
-
2021
- 2021-06-21 AU AU2021204137A patent/AU2021204137A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10113169B2 (en) | 2018-10-30 |
| EP3581653A3 (en) | 2020-02-19 |
| DK3087182T3 (da) | 2019-06-24 |
| EP3087182B1 (en) | 2019-03-20 |
| US10858655B2 (en) | 2020-12-08 |
| US20160319284A1 (en) | 2016-11-03 |
| AU2014370182B2 (en) | 2021-07-15 |
| US20190284561A1 (en) | 2019-09-19 |
| JP2017502040A (ja) | 2017-01-19 |
| CA2934524A1 (en) | 2015-07-02 |
| WO2015100113A2 (en) | 2015-07-02 |
| EP3087182A4 (en) | 2017-08-23 |
| CA3142856A1 (en) | 2015-07-02 |
| US11518996B2 (en) | 2022-12-06 |
| JP6537513B2 (ja) | 2019-07-03 |
| AU2014370182A1 (en) | 2016-07-28 |
| ES2741811T3 (es) | 2020-02-12 |
| US20200370049A1 (en) | 2020-11-26 |
| WO2015100113A3 (en) | 2015-10-29 |
| CA2934524C (en) | 2022-02-15 |
| AU2021204137A1 (en) | 2021-07-15 |
| EP3087182A2 (en) | 2016-11-02 |
| EP3581653A2 (en) | 2019-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282202A (en) | Compositions and methods for personalized neoplasia vaccines | |
| IL283660A (en) | Compositions and methods for modulating apolipoprotein (a) expression | |
| IL259795A (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| BR112015028115A2 (pt) | métodos e composições para o tratamento de câncer | |
| PL4332576T3 (pl) | Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane | |
| PL3060237T3 (pl) | Zmodyfikowane białko przeprogramowujące do stosowania w leczeniu raka | |
| IL245778B (en) | Methods and preparations for the treatment of hemophilia | |
| IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
| SI3350157T1 (sl) | Sestave za doziranje terapevtskih sredstev v celice | |
| PL3074035T3 (pl) | Kompozycje zawierające przeciwciała anty-CEACAM1 i anty-PD do terapii raka | |
| PL3007695T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| LT3119808T (lt) | Antikūnų kompozicijos vėžio gydymui | |
| BR112017011771A2 (pt) | métodos e composições para o tratamento de câncer | |
| EP3035910A4 (en) | COMPOSITIONS AND METHOD FOR TREATING HAIR | |
| EP2953474A4 (en) | COMPOSITIONS AND METHODS | |
| ZA201505390B (en) | Compositions and methods for treating pests | |
| SG10201707319UA (en) | Compositions and methods for treating mpsi | |
| CY2020029I1 (el) | Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1 | |
| EP2958571C0 (en) | DNA HYPOMETHYLING AGENTS FOR CANCER THERAPY | |
| PL3186244T3 (pl) | Analogi dioksolanowe urydyny w leczeniu raka | |
| PL3200815T3 (pl) | Sposoby i kompozycje do leczenia nowotworu | |
| PL3087182T3 (pl) | Sposoby i kompozycje do leczenia raka wykorzystujące środki oparte na kwasie peptydonukleinowym | |
| HUE046596T2 (hu) | Eljárások mitokondriális betegség kezelésére | |
| HUE060909T2 (hu) | Mûtrágya készítmények | |
| HRP20182041T1 (hr) | Pripravci oksprenolola za liječenje raka |